Neurophth Therapeutics / 纽福斯生物科技有限公司

• 14/08/2023
• Series C
• $95,000,000

At Neurophth, we walk from obstacle to obstacle without loss of enthusiasm.
在纽福斯公司，我们是从一个障碍走向另一个障碍而不丧失热情。

We are China’s first gene therapy company for ophthalmic diseases. Our mission is building a brighter future for patients by innovative gene therapies.

Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and USA, we are striving to discover and develop gene therapies for patients suffering from blindness and other eye diseases globally. We leverage our AAV and CMC platforms to regain vision in patients suffering from Leber’s hereditary optic neuropathy (LHON), autosomal dominant optic atrophy, vascular retinopathy (wAMD, DME, etc), optic neuropathy (glaucoma, etc) and other genetic diseases. Our most advanced investigational candidate, NR082 (rAAV2-ND4), in development for the treatment of LHON associated with ND4 mutation using a single administration through less invasive intravitreal injection, has received orphan disease designations in the U.S.

We are always seeking highly motivated and talented individuals with diverse experiences, abilities and interests who are seeking to inspire the world and help patients to restore vision to join us on our journey. To learn more about Neurophth and our open positions, visit www.neurophth.com.

---

---